{
  "trial_id": "NCT01853748",
  "overall_assessment": "likely_eligible",
  "inclusion": [
    {
      "criterion": "HER2-positive Stage I histologically confirmed invasive carcinoma of the breast",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "ER/PR determination is required",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "Bilateral breast cancers that individually meet eligibility criteria are allowed",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "Subjects with multifocal or multicentric disease are eligible as long as each tumor individually meets eligibility criteria",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "Should have tumor tissue available and a tissue block of sufficient size to make 15 slides, which must be sent to a DFCI site for testing",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "Less than or equal to 90 days since most recent breast surgery for this breast cancer",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "All tumor should be removed by either a modified radical mastectomy or a segmental mastectomy (lumpectomy) with either a sentinel node biopsy or axillary dissection",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "All margins should be clear of invasive cancer or DCIS",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "May have received up to 4 weeks of tamoxifen therapy or other hormonal therapy, for adjuvant therapy for this cancer",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "Prior oophorectomy for cancer prevention is allowed",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "Subjects who have undergone partial breast radiation (duration <= 7 days) prior to registration are eligible. Partial breast radiation must be completed prior to 2 weeks before starting protocol therapy.",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "Must have discontinued any investigational drug at least 2 weeks prior to participation",
      "label": "met",
      "evidence": "quote"
    }
  ],
  "exclusion": [
    {
      "criterion": "Pregnant or breastfeeding",
      "label": "not_met",
      "evidence": "none"
    },
    {
      "criterion": "Use of potent CYP3A4 inhibitors during the study treatment period",
      "label": "unknown",
      "evidence": "none"
    },
    {
      "criterion": "Excessive alcohol intake (more than 3 alcoholic beverages per day)",
      "label": "not_met",
      "evidence": "none"
    },
    {
      "criterion": "Locally advanced tumors at diagnosis",
      "label": "not_met",
      "evidence": "none"
    },
    {
      "criterion": "History of previous invasive breast cancer",
      "label": "unknown",
      "evidence": "none"
    },
    {
      "criterion": "History of prior chemotherapy in the past 5 years",
      "label": "unknown",
      "evidence": "none"
    },
    {
      "criterion": "History of prior trastuzumab or prior paclitaxel therapy",
      "label": "not_met",
      "evidence": "none"
    }
  ],
  "notes": "Patient is a postmenopausal woman with HER2-positive breast cancer, meeting most eligibility criteria. However, history of previous invasive breast cancer and prior chemotherapy in the past 5 years are unknown.",
  "_meta": {
    "topic_id": "25",
    "trial_id": "NCT01853748",
    "model": "llama3.1:8b",
    "run_tag": "llama31_8b_full_top100",
    "top_k": 100
  }
}